About
Shenzhen Baiyin Biotechnology, founded in 2021 by SIAT researcher Zhong Chao and Cui Junfeng, develops protein and polysaccharide bio-based materials such as recombinant mussel adhesive protein using synthetic biology, AI, enzyme engineering and protein-design platforms for pharma, medical aesthetics, cosmetics and food.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 4
Founders / team· 2
Funding history
- 2026-10-22Series A$28M
Investors · L' Oreal Groupe, 沃博联, 广药集团, 广新集团Source · chinaventure.com.cn ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- PAM2L Biotechnologies
Shenzhen Baiyin Biotechnology, founded in 2021 by SIAT researcher Zhong Chao and Cui Junfeng, develops protein and polysaccharide bio-based materials such as recombinant mussel adhesive protein using synthetic biology, AI, enzyme engineering and protein-design platforms for pharma, medical aesthetics, cosmetics and food.
Series A · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- Generate Biomedicines
Generative AI drug development company incubated by Flagship Pioneer, using machine learning to design and create new proteins that can be used to treat diseases
Series C · $693M · 2023-09
$693M - Engine Biosciences
Uses machine learning and biology to discover and develop precision oncology drugs
Series A · $27M · 2023-11
$27M - Odyssey Therapeutics
Small-molecule and protein therapeutics developed with AI and machine learning
Series C · $101M · 2023-12
$101M
China
BusinessLatest roundTotal raisedDate- 中科欣扬
Synthetic biology platform built on extremophile microbial resources, developing bioactive ingredients for the pharmaceutical, food and cosmetics industries; commercialized products include ergothioneine, NMN and vanillin.
Series C · $42M · 2026-07
$42M - QL Biopharmaceutical
Novel recombinant protein drugs from an E. coli expression platform for chronic metabolic diseases such as obesity, type 2 diabetes and MASH
Series C · 2026-09
— - Purui Intelligence
AI-driven platform for end-to-end clinical trial automation and results delivery.
Series A · $14M · 2026-06
$14M
Europe
BusinessLatest roundTotal raisedDate- Generare
Small-molecule discovery driven by AI and synthetic biology
Series A · $46M · 2026-04
$46M - Enodia Therapeutics
Proteomics and machine learning-based small-molecule targeted protein degradation (TPD) platform
Seed · $25M · 2026-01
$25M - Biographica
Uses machine learning to identify gene-editing targets in crops, accelerating breeding R&D
Seed · $149M · 2026-01
$149M
Other / unspecified
BusinessLatest roundTotal raisedDate- Recursion Pharmaceuticals
AI drug discovery platform using high-throughput cell imaging and machine learning, with an in-house pipeline
— - OutPost Bio
Automated wet lab + machine learning to generate human microbiome data and predict microbial effects of drugs/products
Pre-Seed · $7M · 2026-03
$7M - XtalPi
AI + robotics drug and materials R&D, quantum physics first-principles computation, automated labs, R&D solutions
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in South China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 5 at a nearby stage · 4 in South China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 6 at a nearby stage · 7 in South China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 6 at a nearby stage · 7 in South China
Request intro →HongShan
7 Life Sciences deals in the last 24 months · 3 at a nearby stage · 6 in South China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 6 at a nearby stage · 4 in South China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.